Intellia Therapeutics Inc (NTLA)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$12.93
Buy
$13.07
$-0.14 (-1.05%)
Prices updated at 03 Apr 2026, 00:55 EDT
| Prices minimum 15 mins delay
Prices in USD
Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 58m | 68m | |
| - | - | |
| -534m | -441m | |
| -923.10 | -651.67 | |
| -519m | -413m | |
| -524m | -425m | |
| Sales, General and administrative | 126m | 120m |
| Interest expenses | - | - |
| Provision for income taxes | - | - |
| Operating expenses | 592m | 509m |
| Income before taxes | -519m | -413m |
| Net income available to common shareholders | -519m | -413m |
| -5.25 | -3.81 | |
| Net interest income | 48m | 29m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -5.25 | -3.81 |
| Free cash flow per share | -3.7819 | -3.9355 |
| Book value/share | 9.4347 | 6.4343 |
| Debt equity ratio | 0.217846 | 0.099567 |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 640m | 528m |
| Current liabilities | 111m | 104m |
| Total capital | 872m | 671m |
| Total debt | 210m | 93m |
| Total equity | 872m | 671m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 1,191m | 842m |
| Total liabilities | - | - |
| Cash and cash equivalents | 189m | 155m |
| Common stock | 102m | 116m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 240m | 203m |
| Cash dividends paid | - | - |
| -355m | -396m | |
| Investments (gains) losses | 126m | 228m |
| 203m | 168m | |
| Net income | - | - |
| -349m | -395m | |
| -6m | -1m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
